Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review

Papers of special note have been highlighted as: • of interest

References

• 1 Steensma DP. Oddballs: acute leukemias of mixed phenotype and ambiguous origin. Hematol. Oncol. Clin. N. Am. 25(6), 1235–1253 (2011).
  MedlineGoogle Scholar
• 2 Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood 125(16), 2477–2485 (2015).
  Medline CASGoogle Scholar
• 3 Matutes E, Pickl WF, Van't Veer M et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 117(11), 3163–3171 (2011).
  Medline CASGoogle Scholar
• 4 Aribi A, Bueso-Ramos C, Estey E et al. Biphenotypic acute leukaemia: a case series. Br. J. Haematol. 138(2), 213–216 (2007).
  MedlineGoogle Scholar
• 5 Yan L, Ping N, Zhu M et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 97(11), 1708–1712 (2012).
  MedlineGoogle Scholar
• 6 Kim HJ. Mixed-phenotype acute leukemia (MPAL) and beyond. Blood Res. 51(4), 215–216 (2016).
  MedlineGoogle Scholar
• 7 Weir EG, Ali Ansari-Lari M, Batista DA et al. Acute bilineal leukemia: a rare disease with poor outcome. Leukemia 21(11), 2264–2270 (2007).
  Medline CASGoogle Scholar
• 8 Van Den Ancker W, Westers TM, De Leeuw DC et al. A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytometry B Clin. Cytom. 84(2), 114–118 (2013).
  MedlineGoogle Scholar
• 9 Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20), 2391–2405 (2016).
  Medline CASGoogle Scholar
• 10 Charles NJ, Boyer DF. Mixed-phenotype acute leukemia: diagnostic criteria and pitfalls. Arch. Pathol. Lab. Med. 141(11), 1462–1468 (2017).
  Medline CASGoogle Scholar
• 11 Pomerantz A, Rodriguez-Rodriguez S, Demichelis-Gomez R et al. Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used. Blood Res. 51(4), 233–241 (2016).
  MedlineGoogle Scholar
• 12 Shimizu H, Saitoh T, Machida S et al. Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur. J. Haematol. 95(5), 455–460 (2015).
  MedlineGoogle Scholar
• 13 Tian H, Xu Y, Liu L et al. Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk. Res. 45, 40–46 (2016).
  Medline CASGoogle Scholar
• 14 Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica 102(12), 2134–2140 (2017).
  MedlineGoogle Scholar
• 15 Getta BM, Roshal M, Zheng J et al. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning is associated with favorable outcomes in mixed phenotype acute leukemia. Biol. Blood Marrow Transplant. 23(11), 1879–1886 (2017).
  MedlineGoogle Scholar
• 16 Hoffmann P, Hofmeister R, Brischwein K et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115(1), 98–104 (2005).
  Medline CASGoogle Scholar
• 17 Topp MS, Gokbuget N, Zugmaier G et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32(36), 4134–4140 (2014).
  Medline CASGoogle Scholar
• 18 Ueda M, De Lima M, Caimi P et al. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 51(9), 1253–1255 (2016). • This is the first report on the concurrent use of blinatumomab and donor lymphocyte infusion (DLI) in patients with relapsed B-acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation.
  Medline CASGoogle Scholar
• 19 Topp MS, Gökbuget N, Stein AS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, Phase II study. Lancet Oncol. 16(1), 57–66 (2015). • This study has led to US FDA approval of blinatumomab for Ph-relapsed or refractory B-ALL. Complete remission (CR) was reported at 33% (63 of 189 patients), and CR with partial hematologic recovery (CRh) 10% (18 of 189 patients) after two cycles of therapy. Median relapse-free survival (RFS) was 5.9.
  Medline CASGoogle Scholar
• 20 Wolach O, Stone RM. Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Curr. Opin. Hematol. 24(2), 139–145 (2017).
  MedlineGoogle Scholar
• 21 Maruffi M, Sposto R, Oberley MJ, Kysh L, Orgel E. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia 32(7), 1515–1528 (2018).
  MedlineGoogle Scholar
• 22 Kantarjian H, Stein A, Gokbuget N et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376(9), 836–847 (2017). • A Phase III TOWER study demonstrated a statistically significant difference in overall survival (OS) between blinatumomab (7.7 months) and chemotherapy arm (4 months). CR rate was 34 and 16% in the blinatumomab and chemotherapy group, respectively. MRD negativity status noted as 76% in the responders who achieved CR (full, partial or incomplete hematologic recovery) and 48% in the chemotherapy group.
  Medline CASGoogle Scholar
• 23 Gokbuget N, Dombret H, Bonifacio M et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14), 1522–1531 (2018).
  MedlineGoogle Scholar
• 24 Collins RH Jr, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26(5), 511–516 (2000).
  MedlineGoogle Scholar
• 25 He F, Warlick E, Miller JS et al. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant. 51(8), 1107–1112 (2016).
  Medline CASGoogle Scholar
• 26 El Chaer F, Ali OM, Sausville EA et al. Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. Am. J. Hematol. 94(1), E7–E8 (2019).
  MedlineGoogle Scholar
• 27 Alcharakh M, Yun S, Dong Y et al. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. Immunotherapy 8(8), 847–852 (2016).
  CASGoogle Scholar
• 28 Hamdi A, Mawad R, Bassett R et al. Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 20(11), 1767–1771 (2014).
  MedlineGoogle Scholar
• 29 Bondarenko SN, Maschan AA, Parovichnikova EN et al. The efficacy and toxicity of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia: Russian multicenter experience. Blood 130(Suppl 1), 2604–2604 (2017).
  Google Scholar
• 30 Linder K, Gandhiraj D, Hanmantgad M, Seiter K, Liu D. Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp. Hematol. Oncol. 5, 20 (2015).
  MedlineGoogle Scholar
• 31 Khan MW, Gul Z. Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant. Clin. Case Rep. 4(8), 743–746 (2016).
  MedlineGoogle Scholar
• 32 Ronchetti AM, Leboeuf C, Raffoux E et al. Graft versus leukemia could participate of efficacy of blinatumomab in patients with B-lineage acute lymphoid leukemia relapsing after stem cell transplantation. J. Stem. Cell Res. Ther. 4(11), 251 (2014).
  Google Scholar
• 33 Paul S, Regul L, Vollstadt O et al. Concurrent blinatumomab and donor lymphocytes for relapse of acute lymphoblastic leukemia after 2nd allogeneic transplantation-a case report. Bone Marrow Transplant. 52, S392–S393 (2017).
  Google Scholar